2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 6, 2015
Mallinckrodt Accents Critical Care With Ikaria Acquisition
Author(s)Pharmaceutical Technology Editors
Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.
Advertisement
Mallinckrodt Pharmaceuticals, a specialty biopharmaceutical company, has inked a deal for $2.3 billion with Ikaria, a privately-held critical care company focused on the development and commercialization of innovative
therapies and delivery systems. The deal is expected to increase Mallinckrodt's net sales by $150 million.
Ikaria's leading product, FDA-approved Inomax, is a vasodilator that is designed for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure, in conjuction with ventilatory support and
other treatments. Inomax improves oxygenation and reduces the need for extracorporeal membrane oxygenation and is specifically indicated for patients experiencing hypoxic respiratory failure associated with clinical
or endocardiographic evidence of pulmonary hypertension, according to a press release.
Source:
Advertisement
Related to this article
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Advertisement
Advertisement